# Trifluridine + Tipiracil

## Lonsurf 20mg

##### 臨採

| TAH Drug Code      | [OLONS](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OLONS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Metastatic colorectal cancer in adults                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Dosing             | 35 mg/m2 (based on the trifluridine component) twice daily on days 1 to 5 and days 8 to 12 of a 28-day cycle (maximum per dose: trifluridine 80 mg); continue until disease progression or unacceptable toxicity. The manufacturer recommends rounding each dose to the nearest 5 mg increment.                                                                                                                                                                                                                                                                           |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Contraindications  | There are no contraindications listed in the manufacturer's labeling.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Adverse Effects    | >10%: Fatigue (52%), Nausea (37% to 48%), decreased appetite (34% to 39%), diarrhea (23% to 32%), vomiting (25% to 28%), abdominal pain (21%), Anemia (63% to 77%; grades 3/4: 18% to 19%), neutropenia (66% to 67%; grades 3/4: 38%;), thrombocytopenia (34% to 42%; grades 3/4: 5% to 6%), febrile neutropenia (grades 3/4: 3%), Infection (23% to 27%), Asthenia (?52%), Fever (19%) 1% to 10%: Pulmonary embolism (2% to 3%), Alopecia (7%), Stomatitis (8%; grades 3/4: <1%), dysgeusia (7%) <1%: postmarketing, and/or case reports: Interstitial pulmonary disease |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| More Info          | [UpToDate](https://www.uptodate.com/contents/trifluridine-+-tipiracil-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

